caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1407820657

Luis Valledor MaesoMD

OtolaryngologyBayamon, PRI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
REFERRAL NETWORK

Where Luis Valledor Maeso's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 1 inbound referrers · 2 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
Jose De Leon-Jimenez
Otolaryngology · Carolina, PR
1721
Refers patients to
Outbound — where patients go next
PhysicianPatientsVisits
Jose Sanchez-Mendiola
Otolaryngology · Bayamon, PR
2730
Jose De Leon-Jimenez
Otolaryngology · Carolina, PR
1821
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
97
Unique beneficiaries
—
Total services
126
Distinct HCPCS
4
Medicare payment
$8K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 54 Otolaryngology providers in PR — above median (cohort median 146).
PRESCRIBING · PART D · 2024
Total Rx claims
2,390
Beneficiaries
—
Total drug cost
$45K
Distinct drugs
17
Brand share
3.6%
Top prescribed drugs
Fluticasone Propionate844 claims
Azelastine Hcl586 claims
Famotidine373 claims
Ofloxacin117 claims
Levofloxacin92 claims
QUALITY · MIPS · 2024
No data available for this provider in 2024.
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
No data available for this provider in 2024.